Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 22;13:5555. doi: 10.1038/s41467-022-33148-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022, corrected publication 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — Topical treatment with 1.5% PXS-6302 cream significantly inhibited LOX activity (a (p = 0.001)), reduced hydroxyproline (b (p = 0.048)) and immature DHLNL (c (p < 0.0001)) and HLNL (d (p < 0.0001)) crosslinks in the skin and reduced fibrosis as assessed by dermal thickness (e (p = 0.0139 and 0.0013 vehicle and naïve vs PXS-6302 treated respectively)) and Composite skin scores (f (p = 0.0114)). Immunohistochemistry also showed reduced Col I (g (p = 0.0006)) and LOX (h (p < 0.0001)) positive staining in 1.5% PXS-6302 treated tissue sections. Naïve animals were not exposed to bleomycin, whilst vehicle and PXS-6302 groups were treated with bleomycin to induce fibrosis (n = 9–10 per group). Statistical analysis was performed with two-tailed Mann–Whitney test or one-way ANOVA with Tukey’s method for multiple comparisons. p values are <0.05 (*), <0.01 (**), <0.001 (***) and <0.0001 (****). Source data are provided as a Source Data file.